Session Time: 6:00pm-7:00pm
Presentation Time: 6:00pm-7:00pm
Location: Hall C & D
*Purpose: Diabetes after renal transplantation is one of the most serious complications after renal transplantation. It has a serious impact to the survival of kidney graft; the quality of life and survival rate of transplant recipients. Currently, it mainly relies on medical treatment, but the medical treatment program does not satisfactory, and the long-term treatment affect is poor curative. With the promotion of the concept of organ donation after the death of citizens, allogeneic islet transplantation for the treatment of diabetes has gradually attracted people’s attention. However, the clinical efficacy of islet transplantation after renal transplantation needs to be evaluated.
*Methods: We first selected 8 eligible diabetic patients with renal transplantation according to the criteria for inclusion and exclusion of allogeneic islet transplantation. Combined with the technical specifications of the islet cell transplantation Edmonton protocol, we set the following islet cell extraction criteria: islet cell purity > 5000 IEQ / kg, islet cell viability > 70%, islet cell purity > 30%, glucose stimulation index > 1, Gram Staining (-), endotoxin detection <5U / kg, islet cells were injected into the recipient liver through the portal vein. The patient's clinical detection index was tracked in real time, and the clinical treatment effect of allogeneic islet transplantation on the improvement of diabetes after renal transplantation was analyzed.
*Results: By tracking the clinical data of diabetic patients after renal transplantation, the average rate of random fasting blood glucose decreased by 3.36±1.24 mmol/L in the three months after islet transplantation, and the mean decrease in insulin use was 21.75±3.65 IU. The average of glycated serum protein was decreased. The value was 124.18±9.88 umol/L, and the clinical symptoms such as thirst and polyuria were also improved. At the same time, the decrease of fasting blood glucose was negatively correlated with the fasting blood glucose level before transplantation (p <0.05), and the decrease of glycated serum protein was negatively correlated with the concentration of glycated serum protein before transplantation (p <0.05). There were no significant differences in renal function tests between patients during islet transplantation.
*Conclusions: Allogeneic islet transplantation technology has proved to be simple operation and safe treatment, it has no obvious effect on renal function after transplantation, and can significantly ameliorate the clinical symptoms of patients.
To cite this abstract in AMA style:liang W, Hu M, Peng G, Zhou D, Zeng C, Zhou W, Ye q, Wang Z. Clinical Trial of Allogeneic Islet Transplantation in the Treatment of Diabetes after Renal Transplantation [abstract]. Am J Transplant. 2019; 19 (suppl 3). https://atcmeetingabstracts.com/abstract/clinical-trial-of-allogeneic-islet-transplantation-in-the-treatment-of-diabetes-after-renal-transplantation/. Accessed August 12, 2020.
« Back to 2019 American Transplant Congress